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Cancer survival differences
between European
populations: the UK
uneasiness
In no country has the impact of EUROCARE (Berrino et al, 1995,
1999; Coebergh et al, 1998; Capocaccia et al, 2001) – which
provides a comparative analysis of cancer survival in Europe –
been so great as the UK. This is doubtless due to the surprisingly
low level of survival found for British patients compared to those
in most other western European countries. And it is understand-
able that a debate on the interpretation and validity of the EURO-
CARE results should have arisen. The paper by Woodman and
co-workers (2001) in this issue is a further contribution to this
debate. It presents a detailed critique of some of the methods 
of EUROCARE and concludes that survival data from many
European cancer registries may be flawed so it would be more
appropriate to compare UK survival data (which is not flawed)
with that from Scandinavian countries (which is also reliable).
Nevertheless Woodman et al (2001) concede that UK survival is
worse than that of most Scandinavian countries and argue for
immediate measures to identify and rectify suboptimal care. 
One issue raised indirectly by the paper of Woodman et al
(2001) is whether international comparison of survival, based on
cancer registry data, is useful at all, because different registries use
different diagnostic procedures, different follow-up procedures
and have variable completeness of coverage. In particular
Woodman et al suggest that survival may be inflated in some
registries because of failure to identify all cases of advanced
disease. This is an important issue but one that has been fully
addressed in EUROCARE publications. These ‘incompatibilities’
can be analysed individually and their impact on survival figures
estimated. It is found that the confounders have a small effect on
the data and intercountry differences in survival persist after taking
account of them (Berrino et al, 1995, 1999, 2001). It is noteworthy
that intercountry survival differences reduce or even disappear
altogether for cancers such as testicular cancer, Hodgkin’s disease,
and several childhood cancers, for which highly effective treat-
ments exist. If the survival differences observed for the major
cancer sites – colon, rectum, melanoma, breast, prostate – are due
to registration or follow-up bias, one wonders why similar differ-
ences are not observed for all cancer sites. 
The assertion of Woodman et al that UK survival rates can only
reliably be compared with those of Finland and Scandinavia,
reflects, in our opinion, a prejudice that the quality of incidence
and survival data is lower in southern European countries. There is
no evidence to support this prejudice. Many southern European
cancer registries have quality and exhaustiveness indicators as
good as the best in northern Europe (Parkin et al, 1997). It is true
that cancer registration developed later in southern Europe, and
small regional registries were set up rather than national ones; but,
exploiting the experience of the longer-established registries, they
set-up links with numerous sources of information from the outset,
usually including population files of residents, and implemented
efficient systems of active quality control and follow-up (Berrino
et al, 1995, 1999; Parkin et al, 1997). Of course, the extent to
which a series of small registries covering a small fraction of the
national territory provides a representative picture of the whole
country remains an issue – as repeatedly emphasised in EURO-
CARE publications. In Italy, for instance, cancer patients’ survival
is higher in the north of the country, where coverage is also higher
(Veradecchia et al, 1997). Ecological techniques to model national
data from the data provided by local registries have recently been
proposed (Mariotto et al, 2001). In any event the issue of national
representativeness should not be allowed to cast doubt on the legit-
imacy of comparing incidence and survival between population-
based registries. 
A further criticism concerns the difficulty of interpreting
survival differences because of missing information on stage and
other clinical variables. The high resolution (HR) studies that
collect standardised information on stage, staging procedures and
treatment from small samples of incident cases were conceived to
address this issue. HR studies permit stage-specific and stage-
adjusted survival comparisons corrected for stage migration, i.e.
corrected for the fact that staging examinations, practices and
facilities vary. However, they are expensive and difficult to carry
out because they require direct access to clinical records. Only a
few registries have such access or the resources to gather informa-
tion from them. In HR studies, the cases examined do not have to
be representative of the national population, but should be repre-
sentative of the registry population, as recognised in the Woodman
paper. To ensure this, HR studies should be nested with general
survival studies. 
So far cancer registries have only been able to submit small
numbers of cases for HR studies. As a consequence, the results 
are uncertain and the conclusions preliminary. The paper by
Woodman et al draws attention to several inconsistencies between
survival rates estimated from a few hundred cases included in the
recent HR study (Gatta et al, 2000) and those obtained from many
thousands of cases diagnosed in a previous period and included in
the main EUROCARE II study. It is right that such inconsistencies
should be pointed out; in fact they were not unexpected given that
the study periods differ, and survival rates are changing. These
authors highlighted in particular that in the HR study (Gatta et al,
2000) the population of the Modena registry did not perfectly
coincide with that presented in the EUROCARE II monograph.*
Clearly further HR studies on larger samples are required to
clarify how much intercountry survival differences are due to differ-
ential delay in diagnosis and how much to differences in treatment. 
To return to more general matters. Some authors feel that moni-
toring other types of data is more useful than monitoring survival, or
even that population-based survival data are useless (Irwig et al,
2000; Peto et al, 2000). Our opinion is that mortality data and
adequacy of treatment data are useful, but cannot be fully interpreted
without corresponding survival data. Moreover, mortality and treat-
ment data are not without defects. It is true, however, that survival
figures are often published after a long delay, and this is unfortunate
when short-term survival is informative. EUROCARE is moving
toward a more timely centralisation and analysis of survival data. 
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*In this paper (Gatta et al, 2000) the HR data for Modena were restricted to cases
diagnosed in 1990–91 and from a smaller (urban) area than that considered in
EUROCARE II (1985–1989) which included cases diagnosed in the whole province in
1988–89. The HR study was in fact confined to the Modena colorectal cancer registry
which covers only part of the province. The incidence in 1990–91 was 315 cases, 306
of which were eligible for inclusion in the study (Ponz de Leon et al, 1998). 
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is poorer in the UK than in the countries they consider worthy
comparators, and suggest that access to effective treatment is
important, recommending systematic audits of treatment quality.
We agree that audit studies are important, but in order to inform
the interpretation of future mortality and survival trends, they
should be population-based – and this will be even more difficult
than carrying out retrospective registry-based studies of patterns of
care, as done by EUROCARE. Finally, whatever action the UK
government takes to improve cancer survival, population-based
survival studies will be a necessary check that their intervention
has been effective. 
Woodman et al (2001) also correctly point out an inconsistency
between the observed and relative survival figures. The Gatta et al
paper (Gatta et al, 2000) erroneously reported the differences
between observed and relative survival. In fact, differences at three
years were larger than reported but the rank of countries did not
change and the hazard ratios based on relative survival changed
only slightly. We preferred to present the results with the more
familiar Cox model also due to its higher statistical power. 
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